There is substantial evidence, both pharmacological and genetic, that hypofunction of the N-methyl-D-aspartate receptor (NMDAR) is a core pathophysiological feature of schizophrenia. There are morphological brain changes associated with schizophrenia, including perturbations in the dendritic morphology of cortical pyramidal neurons and reduction in cortical volume. Our experiments investigated whether these changes in dendritic morphology could be recapitulated in a genetic model of NMDAR hypofunction, the serine racemase knockout (SR−/−) mouse. Pyramidal neurons in primary somatosensory cortex (S1) of SR−/− mice had reductions in the complexity, total length, and spine density of apical and basal dendrites. In accordance with reduced cortical neuropil, SR−/− mice also had reduced cortical volume as compared to wild type mice. Analysis of S1 mRNA by DNA microarray and gene expression analysis revealed gene changes in SR−/− that are associated with psychiatric and neurologic disorders, as well as neurodevelopment. The microarray analysis also identified reduced expression of brain derived neurotrophic factor (BDNF) in SR−/− mice. Followup analysis by ELISA confirmed a reduction of BDNF protein levels in the S1 of SR−/− mice. Finally, S1 pyramidal neurons in glycine transporter heterozygote (GlyT1+/−) mutants, which display enhanced NMDAR function, had increased dendritic spine density. These results suggest that proper NMDAR function is important for the arborization and spine density of pyramidal neurons in cortex. Moreover, they suggest that NMDAR hypofunction might, in part, be contributing to the dendritic and synaptic changes observed in schizophrenia and highlight this signaling pathway as a potential target for therapeutic intervention.
Introduction
Schizophrenia is a complex mental disorder that is clinically characterized by positive symptoms, negative symptoms, and cognitive deficits. Over the past two decades, there has been converging evidence supporting the hypothesis that N-methyl-D-aspartate receptor (NMDAR) hypofunction is a key component in the etiology of schizophrenia (Coyle, 2006; Javitt and Zukin, 1991; Krystal et al., 1994; Tsai et al., 1995) .
Activation of NMDARs requires the binding of either glycine or D-serine at the glycine modulatory site (GMS) on the NR1 subunit (Kishi and Macklis, 2004) . D-Serine is enriched in corticolimbic regions of the brain, where its localization closely parallels that of NMDARs (Schell et al., 1995) . The finding that D-serine is decreased in cerebrospinal fluid and serum samples from individuals with schizophrenia (Hashimoto et al., 2003 (Hashimoto et al., , 2005a ) is consistent with the hypothesis that lower D-serine is part of the pathophysiology of the disorder. A single nucleotide polymorphism (SNP) in the gene encoding serine racemase (SR), the enzyme that produces D-serine from L-serine, has also been associated with schizophrenia (Morita et al., 2007) . This mutation results in reduced expression of SR protein. G72, the gene product of which regulates D-serine levels by modulating the activity of D-amino acid oxidase (Sacchi et al., 2008) , has been implicated as a risk gene for schizophrenia (Bass et al., 2009; Shi et al., 2008) . A recent meta-analysis found that treatment with GMS agonists, including D-serine, exerted significant therapeutic effects on multiple symptom domains in schizophrenia (Tsai and Lin, 2010) .
In addition to modified GMS occupancy, NMDAR hypofunction in schizophrenia could also be due to postsynaptic deficits in NMDARmediated signaling. Although the findings in postmortem studies of NMDAR transcripts and protein expression levels in schizophrenia have been modest and inconsistent (Lewis and Gonzalez-Burgos, 2008) , recent evidence suggests that other components of NMDAR signaling, as well as receptor processing and trafficking might be affected in the illness (Kristiansen et al., 2010a,b) . Moreover, postmortem studies indicate that the endogenous NMDAR antagonists, kynurenic acid and N-acetyl-aspartyl glutamate are elevated in schizophrenia (Erhardt et al., 2007; Tsai et al., 1995) . 
